摘要
背景: 帕金森患者常常靠补充外源性多巴胺来平衡神经递质失调, 长期服用, 易产生耐药性, 故未从根本上解决神经受损的问题。大量研究显示神经节苷脂有促进神经轴突生长和神经营养作用, 并且对谷氨酸介导的细胞毒作用有很大的抵抗作用。目的: 观察口服国产神经节苷脂对帕金森病患者临床症状的改善时间及效果。设计: 回顾性病例分析。单位: 上海电力医院内科, 昆明医学院第一附属医院神经外科 / 内科。对象: 于 2001- 01/2005- 01 通过脑病防治健康教育计划小组选取帕金森患者, 包括黑龙江、河北、山东、河南、北京、江苏、甘肃、青海、贵州、福建、湖南、山西、湖北、四川、重庆、江西、上海、云南等地区共 6 344 例患者, 均符合《实用神经病学》有关帕金森病的诊断及分类标准, 纳入口服神经节苷脂≥ 10 mg/d, 服用 1 个月以上且知情同意者。方法: 患者口服国产神经节苷脂口服液进行神经功能康复, 每支含神经节苷脂( 内含单唾液酸四己糖神经节苷脂 1(21%) 、二唾液酸四已糖神经节苷脂 1 a (40%) 、二唾液酸四已糖神经节苷脂 1 b(16%) 、三唾液酸四已糖神经节苷脂 1 b (19%)0.25 g/L, 每天早上空腹 2 支, 晚上睡前 2支或每晚临睡前 4 支服用。3 个月为 1 个治疗周期, 患者服用两三个周期, 个别病程时间长者服用 4 个周期以上。服用过程中进行定期随访, 观察帕金森患者在震颤、肌强直、运动迟缓、姿势异常等方面的改善情况。疗效评估: 对患者服用国产神经节苷脂口服液后 3 个月、6 个月、9 个月、1 年的病情改善情况进行观察。显效为震颤和肌强直消失, 姿势异常消失, 渐停止服用多巴胺制剂等药物; 好转为上述症状减轻, 多巴胺制剂等药物减少使用( 有效 = 显效 + 好转) ; 无效为上述症状无改善。主要观察指标: 不同服药时间帕金森患者的疗�
BACKGROUND： Patients with Parkinson disease （PD） are always supplied exogenous dopamine so as to balance a disproportion of neurotransmitter. However, a long-term administration may easily cause drug resistance; therefore, it is not able to solve nerve injuries at all. A lot of researches suggest that ganglioside can promote neural axon growth, improve neurotrophy, and resist cellular toxicity mediated by glutamic acid （GA）. OBJECTIVE： To probe into the duration and effect of oral administration of ganglioside on improving clinical symptoms of PD patients. DESIGN： Retrospective case analysis SEI-FING： Department of Internal Medicine, Shanghai Electric Power Hospital; Departments of Neurosurgery and Internal Medicine, the First Affiliated Hospital of Kunming Medical College. PARTICIPANTS： A total of 6 344 PD patients were selected from Heilongjiang, Hebei, Shandong, Henan, Beijing, Jiangsu, Gansu, Qinghai, Guizhou, Fujian, Hunan, Shanxi, Hubei, Sichuan, Chongqing, Jiangxi, Shanghai and Yunnan from January 2001 to January 2005. All patients met the diagnostic and typing criteria of PD in Practical Neurology. They orally took ≥ 10 mg/d ganglioside for more than 1 month, and all of them were provided the consent. METHODS： Patients who were treated with oral ganglioside accepted neural functional rehabilitation. Every oral solution of ganglioside contained 0.25 g/L ganglioside [including monosialoteterahexosyl ganglioside 1 （21%）, diplo-sialoteterahexosyl ganglioside la （40%）, diplo-sialoteterahexosyl ganglioside 1 b （16%）, and tri-sialoteterahexosyl ganglioside lb （19%）], and patients fastingly took two ampoules in every morning and 2 in every evening before sleeping, or took 4 ampoules in every evening before sleeping. Every 3 months was regarded as a course, and patients were always treated for two or three courses; especially, patients having a long-term duration were treated for above 4 courses. Regular follow-up was performed during the administration to observe the improvem
出处
《中国组织工程研究与临床康复》
CAS
CSCD
北大核心
2007年第52期10713-10716,共4页
Journal of Clinical Rehabilitative Tissue Engineering Research
